Purified anti-human CD19 Antibody

Catalog# / Size	302201 / 25 µg 302202 / 100 µg
Clone	HIB19
Regulatory Status	RUO
Workshop	V CD19.11
Other Names	B4
Isotype	Mouse IgG1, κ
Description	CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details

Verified Reactivity	Human
Reported Reactivity	Chimpanzee
Antibody Type	Monoclonal
Host Species	Mouse
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - *Quality tested* CyTOF®, IHC-F - *Verified* PG - *Reported in the literature, not verified in house*
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 10^6 cells in 100 µl volume or 100 µl of whole blood. For immunohistochemistry, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections[8] and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268). Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, *et al.* 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
3. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.
4. Joseph A, *et al.* 2010. *J. Virol.* 84:6645. PubMed
5. Wang X, *et al.* 2010. *Haematologica.* 95:884. (FC) PubMed
6. Walker JD, *et al.* 2009. *J. Immunol.* 182:1548. (Block) PubMed
7. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
8. Hansen A, *et al.* 2002. *Arthritis Rheum.* 46:2160. (IHC)
9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)

10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)

Product Citations

1. Fu J *et al.* 2019. Cell stem cell. 24(2):227-239 . PubMed
2. Dallari S, *et al.* 2017. Nat Commun. 8:14830. PubMed
3. Rouers A, *et al.* 2021. Cell Rep Med. 2:100278. PubMed
4. Weinhage T, *et al.* 2020. J Immunol. 205:56. PubMed
5. Gadalla R, *et al.* 2022. STAR Protoc. 3:101643. PubMed
6. Alroqi F, *et al.* 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
7. Walker J, *et al.* 2009. J Immunol. 182:1548. PubMed
8. Korn MA, *et al.* 2020. J Immunol. 205:2595. PubMed
9. Cao Q, *et al.* 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
10. Gupta R, *et al.* 2022. Front Immunol. 13:886442. PubMed
11. Pugh J, *et al.* 2021. PeerJ. 9:e12258. PubMed
12. Chakhtoura M, *et al.* 2021. PLoS Pathog. 17:e1009732. PubMed
13. Lartey S, *et al.* 2020. J Infect Dis. 221:21. PubMed
14. Mann ER, *et al.* 2020. Sci Immunol. :5. PubMed
15. Kaufmann M, *et al.* 2021. Med. 2(3):296-312.e8. PubMed
16. Winkler M, *et al.* 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
17. Sigal N, *et al.* 2022. Methods Mol Biol. 2543:113. PubMed
18. Zhang Y, *et al.* 2022. Exp Hematol Oncol. 11:15. PubMed
19. Gruber CN, *et al.* 2020. Immunity. 53(3):672-684. PubMed
20. Li Y, *et al.* 2019. Front Immunol. 0.460416667. PubMed
21. Yoshihara S, *et al.* 2019. Front Immunol. 0.545833333. PubMed
22. Smillie CS *et al.* 2019. Cell. 178(3):714-730 . PubMed
23. Liu X, *et al.* 2022. STAR Protoc. 3:101310. PubMed
24. Sun Y, *et al.* 2022. Nat Commun. 13:3916. PubMed
25. Ferdosi SR, *et al.* 2019. Nat Commun. 1.695833333. PubMed
26. Martin JC, *et al.* 2020. Cell. 178(6):1493-1508.e20.. PubMed
27. Cerignoli F, *et al.* 2018. PLoS One. 13:e0193498. PubMed
28. O'Boyle KC, *et al.* 2020. Methods Mol Biol. 2111:1. PubMed
29. Eldredge LC, *et al.* 2019. Am J Physiol Lung Cell Mol Physiol. 317:L49. PubMed
30. Johnston HE, *et al.* 2018. Mol Cell Proteomics. 1.247222222. PubMed
31. Bruno TC, *et al.* 2017. Cancer Immunol Res. 0.831944444. PubMed
32. Corleis B, *et al.* 2017. PLoS One. 12:e0173161. PubMed
33. Speir M,*et al.* 2017. Sci Rep.. 10.1038/s41598-017-14690-5. PubMed
34. Agrawal N, *et al.* 2018. Front Immunol. 2.053472222. PubMed
35. Baskar R, *et al.* 2022. Cell Rep Methods. 2:. PubMed
36. Renand A, *et al.* 2018. J Allergy Clin Immunol. 141:1750. PubMed
37. Del Alcazar D, *et al.* 2019. Cell Rep. 28:3047. PubMed
38. Sattler A, *et al.* 2021. Am J Transplant. 21:87. PubMed
39. Han L, *et al.* 2019. Haematologica. 10.3324/haematol.2018.205534. PubMed
40. Roussel M, *et al.* 2021. Cell Reports Medicine. 2(6):100291. PubMed
41. Chng MHY, *et al.* 2020. Immunity. 51(6):1119-1135.e5.. PubMed
42. Singh AK, *et al.* 2017. Front Immunol. 0.513888889. PubMed
43. Han SS, *et al.* 2018. Oncotarget. 9:3292. PubMed
44. Lee YS, *et al.* 2021. J Immunother Cancer. 9:. PubMed
45. Kato M, *et al.* 2021. PLoS One. 16:e0252116. PubMed
46. Newell KL, *et al.* 2021. PLoS One. 16:e0244855. PubMed
47. Schwabenland M, *et al.* 2021. Immunity. . PubMed
48. Bengsch B *et al.* 2018. Immunity. 48(5):1029-1045 . PubMed
49. Evrard M *et al.* 2018. Immunity. 48(2):364-379 . PubMed
50. De Maeyer RPH, *et al.* 2020. Nat Immunol. 21:615. PubMed
51. Anna F, *et al.* 2021. J Immunother Cancer. 9:. PubMed
52. Crome SQ, *et al.* 2017. Nat Med. 1.213888889. PubMed
53. Afzali B, *et al.* 2017. Nat Immunol. 18:813. PubMed
54. Kennedy-Darling J, *et al.* 2021. Eur J Immunol. 51:1262. PubMed
55. Vanshylla K, *et al.* 2018. Eur J Immunol. 48:441. PubMed
56. Dinh HQ, *et al.* 2020. Immunity. 53(2):319-334.e6. PubMed
57. Crawford LB, *et al.* 2021. J Virol. 95:. PubMed
58. Ainai A, *et al.* 2020. Microbiol Immunol. 64:313. PubMed
59. Martin E, *et al.* 2020. JCI Insight. :5. PubMed
60. Leylek R, *et al.* 2020. Cell Rep. 32:108180. PubMed
61. Lavin Y *et al.* 2017. Cell. 169(4):750-765 . PubMed
62. Chiou SH, *et al.* 2021. Immunity. 54:586. PubMed

RRID

AB_314231 (BioLegend Cat. No. 302201)
AB_314232 (BioLegend Cat. No. 302202)

Antigen Details

Structure Ig superfamily, type I transmembrane glycoprotein, 95 kD

Distribution B lineage (except plasma cells), follicular dendritic cells

Function B cell activation and differentiation

Ligand/Receptor	Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type	B cells, Dendritic cells
Biology Area	Costimulatory Molecules, Immunology
Molecular Family	CD Molecules
Antigen References	1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437. 2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.
Gene ID	930

Related Protocols

Immunohistochemistry Protocol for Frozen Sections

Cell Surface Flow Cytometry Staining Protocol

Other Formats

APC anti-human CD19, Biotin anti-human CD19, FITC anti-human CD19, PE anti-human CD19, PE/Cyanine5 anti-human CD19, Purified anti-human CD19, APC/Cyanine7 anti-human CD19, PE/Cyanine7 anti-human CD19, Alexa Fluor® 488 anti-human CD19, Alexa Fluor® 647 anti-human CD19, Pacific Blue™ anti-human CD19, Alexa Fluor® 700 anti-human CD19, PerCP anti-human CD19, PerCP/Cyanine5.5 anti-human CD19, Brilliant Violet 421™ anti-human CD19, Brilliant Violet 570™ anti-human CD19, Brilliant Violet 650™ anti-human CD19, Brilliant Violet 785™ anti-human CD19, Brilliant Violet 510™ anti-human CD19, Brilliant Violet 605™ anti-human CD19, Brilliant Violet 711™ anti-human CD19, Purified anti-human CD19 (Maxpar® Ready), Alexa Fluor® 594 anti-human CD19, PE/Dazzle™ 594 anti-human CD19, APC/Fire™ 750 anti-human CD19, TotalSeq™-A0050 anti-human CD19, Brilliant Violet 750™ anti-human CD19, TotalSeq™-B0050 anti-human CD19, TotalSeq™-C0050 anti-human CD19, Spark NIR™ 685 anti-human CD19, Ultra-LEAF™ Purified anti-human CD19, APC/Fire™ 810 anti-human CD19, PE/Fire™ 640 anti-human CD19, PE/Fire™ 700 anti-human CD19, TotalSeq™-D0050 anti-human CD19, Spark YG™ 593 anti-human CD19, GMP Pacific Blue™ anti-human CD19, Spark Violet™ 423 anti-human CD19, GMP PE anti-human CD19, GMP APC anti-human CD19, KIRAVIA Blue 520™ anti-human CD19, GMP PerCP/Cyanine5.5 anti-human CD19, GMP PE/Cyanine7 anti-human CD19, Spark Violet™ 500 anti-human CD19

Product Data



Human peripheral blood lymphocytes stained with purified HIB19, followed by anti-mouse IgGs FITC



Human frozen spleen tissue slices were fixed with 4% PFA for ten minutes and blocked with 5% FBS for 30 minutes. Then, the tissue was stained with 10 µg/mL of purified anti-human CD19 antibody (clone HIB19) overnight at 4°C. On the next day, tissue was incubated with Alexa Fluor® 594 Goat anti-mouse IgG (clone Poly4053, red). Nuclei were counter-stained with DAPI (blue). The image was scanned with a 10X objective and stitched with MetaMorph® software.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587